A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

Blood. 2023 May 25;141(21):2654-2657. doi: 10.1182/blood.2023020009.

Authors

Hao Zhao¹, Miao-Yan Zhang¹, Kai-Ni Shen¹, Jun Feng¹, Xin-Xin Cao¹, Ming-Hui Duan¹, Dao-Bin Zhou¹, Lu Zhang¹, Jian Li¹

Affiliation

¹ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

PMID: 36928290
DOI: 10.1182/blood.2023020009

No abstract available

Publication types

Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bortezomib / therapeutic use
Cyclophosphamide / adverse effects
Dexamethasone / adverse effects
Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy
Prospective Studies

Substances

Bortezomib
Cyclophosphamide
Dexamethasone

Associated data

ClinicalTrials.gov/NCT03982771